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Abstract
OBJECTIVE: To evaluate the efficacy of Banxiaxiex-
in Tang compared with Western Medicine in the
treatment of functional dyspepsia (FD) through Me-
ta-analysis.
METHODS: Literature was searched in the follow-
ing databases: MEDLINE, Excerpta Medica Data-
base, Chinese Medical Current Contents, China Sci-
ence and Technology Database, Chinese Biomedi-
cal Literature Database, and China National Knowl-
edge Infrastructure. Randomized controlled trials
evaluating the efficacy of Banxiaxiexin Tang for the
treatment of FD were selected according to certain
standards including clear general situation of pa-
tients, specific diagnostic criteria, definite clinical
outcomes, etc. Articles were evaluated with quality
assessment standards in the Cochrane Handbook
for Systematic Reviews of Interventions. Meta-anal-
ysis was conducted with RevMan 5.0.23 software.
RESULTS: Ten articles with a total of 972 patients
were included. The comparison of efficacy between
Banxiaxiexin Tang and Western Medicine showed a
combined effect size [OR=2.75, 95% CI (1.86-4.07)]
and combined effect of value of Z=5.07 (P<0.000 01),
suggesting a significant difference between the
groups.
CONCLUSION: Banxiaxiexin Tang was more effec-
tive thanWestern Medicine in treating FD.
© 2014 JTCM. All rights reserved.
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INTRODUCTION
Functional dyspepsia (FD) is diagnosed if upper gastro-
intestinal endoscopy shows no structural abnormality
explaining the syndrome consisting of epigastric pain,
burning, fullness, discomfort, early satiety, nausea,
vomiting, and belching. FD is a common symptom
that accounts for 20%-40% of gastrointestinal diseases
in the clinic.1 It is also the most common cause of dys-
pepsia in most Asian populations. A study from Shang-
hai shows that among 782 adult patients with dyspep-
tic symptoms, 69% have FD.2
Clinical practitioners have established a clear diagnos-
tic criteria for FD, the Rome Ⅲ diagnosis standards.
According to the theory of Traditional Chinese Medi-
cine (TCM), FD is a fullness and gastric pain syn-
drome. Despite many prokinetic agents, the treatment
for FD remains a problem for clinicians. Banxiaxiexin
Tang from Shang Han Lun is widely used in the treat-
ment of FD by TCM doctors and has favorable cura-
tive effects.3 Therefore, this study aims to perform a
meta-analysis of all random, controlled clinical trials
available describing the treatment of FD with Banxiax-
iexin Tang to evaluate its curative effects and provide
evidence for doctors treating FD with TCM.
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METHODS
Study selection and search strategy
Literature up to March 31, 2013 was retrieved from:
Medical Literature Analysis and Retrieval System On-
line (MEDLINE), Excerpta Medica Database (EM-
BASE), Chinese Medical Current Contents (CMCC),
China Science and Technology Journal Database
(VIP), Chinese Biomedical Literature Database
(CBM), and China National Knowledge Infrastructure
(CNKI). Keywords were: "Banxiaxiexin Tang/Banxiax-
iexin decoction/Banxiaxiexin," and "functional dyspep-
sia."
Literature from Journal of Traditional Chinese Medi-
cine (English version and Chinese version), Liaoning
Journal of Traditional Chinese Medicine (Chinese ver-
sion), Shanghai Journal of Traditional Chinese Medi-
cine (Chinese version), and Tianjin Journal of Tradi-
tional Chinese Medicine (Chinese version) were manu-
ally searched.
Inclusion criteria
Studies must be randomized controlled trial (RCT), re-
gardless of blinding, and written in Chinese or English.
Studies must also include the following information:
patient age, gender, and case from any source, and have
a clear diagnosis according to the Rome Ⅱ/Ⅲ diagno-
sis standards. For intervention studies must have an ex-
perimental group receiving Banxiaxiexin Tang, and a
control group receiving Western Medicine. For out-
come measures, the diagnostic standards of syndromes
in Chinese traditional medicine new drug clinical re-
search guiding principle,4 the effective rate, cure rate,
recurrence rate, and incidence of adverse events must
be included.
Exclusion criteria
Studies were excluded if they met any of the following
criteria: (a) non-RCTs, such as reviews, summary of ex-
perience, or animal experiments; (b) clinical research
studies with no clear diagnostic criteria; (c) studies not
using Banxiaxiexin Tang as the main means of interven-
tion; or (d) repeatedly published studies.
Assessment of methodological quality
According to the quality criteria in the Cochrane Re-
viewers' Handbook 5.0,5 the bias risk assessment tool
include six aspects: (a) random distribution methods;
(b) allocation concealment; (c) blinding for partici-
pants, practitioners, and outcome assessors; (d) com-
plete outcome data; (e) selective outcome reporting da-
ta; and (f ) other bias sources. Each research result was
judged by these criteria by using: "yes" (low risk of bi-
as), "no" (high risk of bias), or "unclear" (uncertain
risk of bias). Criteria (a), (b), and (c) evaluate the bias
risk of each included study, and the other three criteria
evaluate the research results according to different as-
sessments, emphasizing the influencing degree of bias
on study results from the same paper. Two decision
makers double-checked the evaluation results by ex-
changing ideas.
Data extraction
Two reviewers independently reviewed titles and ab-
stracts, excluded articles not meeting the inclusion cri-
teria, and reviewed the full text. Any controversy was
settled through discussion or with assistance from a
third party. When there was no full text, the original
author(s) of the article was contacted.
Statistical analyses
The statistical package RevMan 5.0.23 (Cochrane col-
laboration, Oxford, UK) was used for data analyses.
Heterogeneity of effect measurements among the select-
ed articles was evaluated by the chi-squared (χ2, or
Chi2) test. A condition of P>0.1 and I2<40% was taken
as evidence of almost no heterogeneity,5 the fixed effect
model would be applied. Otherwise, the random effect
model would be applied. Discrete variables were com-
pared with odds risk (OR), while continuous variables
were compared with weighted mean difference
(WMD), outcomes were expressed with 95% confi-
dence interval (CI), P<0.05 was considered statistically
significant. Hypothesis test, the U test, was used for
overall effect. The results were presented as Z and P val-
ues in the forest plot. Potential publication bias was an-
alyzed with an inverted funnel plot.
RESULTS
Description of included trials
A total of 145 articles were collected according to the
retrieval strategy, including 138 Chinese language stud-
ies and seven English language studies. After full text
review, ten RCTs6-15 met the inclusion criteria. The ten
articles, including one conference paper,10 were all writ-
ten in Chinese and published between 2006 and 2012.
Figure 1 shows the literature-screening procedure.
Literature analysis and quality assessment
The ten included articles (Table 1) contain a total of
972 patients, and each ranged from 60 to 170. Most ar-
ticles reported information of sex, age, disease severity,
and carried out statistical tests. Three8,9,12 of the ten arti-
cles adopted computerized randomization methods,
and the remaining articles did not elaborate randomiza-
tion methods or allocation concealment. None of the
articles reported whether blinding was used, or report-
ed patient dropout. Methodological assessment of all
the included articles is shown in Figures 2 and 3.
Clinical efficacy
Heterogeneity was tested in the ten included articles.
The curative rates of the experimental groups com-
pared with the control groups (χ2=4.39, P=0.88, I2=
0% ) showed that the included articles were clinically
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and statistically heterogeneous. The fixed effect model
was adopted for meta-analysis. Merged OR value was
[2.75, 95% CI (1.86-4.07)]. The overall effect tests (Z=
5.07, P<0.000 01) showed a significant difference in
curative rate between the experimental and control
groups and indicated that Banxiaxiexin Tang had a bet-
ter effect than Western drugs in treating FD (Figure 4).
Publication bias
A funnel graph was drawn with the OR of synthetic
therapeutic effects of the experiment groups to the con-
Figure 1 Flow chart of literature search
Excluded (n=21)
-FD was not diagnosed according to
RomeⅡ/Ⅲ Diagnoses Standard
(n=20)
-The inappropriate comparisons
(n=1)
Included articles
(n=10)
Full-text articles screened
(n=31)
Excluded (n=24)
- Non-RCT studies (n=11)
-Studies not pertinent to FD
(n=1)
- Incorrect intervention
(n=12)
Titles and abstracts
screened (n=55)
Duplicates (n=15)
Animal studies (n=75)
Initial search
(n=145)
Author
Fu GY 20106
Hu XL 20067
Min GB 20098
Qiu CH 20119
Shen H 200910
Shi DJ 200911
Sun GW 201112
Wang Q 201213
Zeng JT 201014
Zhu LY 200815
Treatment case
50
30
30
49
50
60
88
43
30
60
Control case
50
30
30
49
50
60
80
43
30
60
Duration
(weeks)
4
2
4
4
4
4
4
2
4
4
Treatment
Banxiaxiexin Tang
Banxiaxiexin Tang
Banxiaxiexin Tang
Banxiaxiexin Tang
Banxiaxiexin Tang
Banxiaxiexin Tang
Banxiaxiexin Tang
Banxiaxiexin Tang
Banxiaxiexin Tang
Banxiaxiexin Tang
Control
Omeprazole+Domperidon
Domperidone
Mosapride
Domperidone
Domperidone
Domperidone
Domperidone
Mosapride
Domperidone
Mosapride
Outcome
①
①→②
①
①
①
①
①→③
①
①→③→④
①→②
Table 1 Characteristics of the included articles
Notes:①: total effective rate;②: motilin;③: electrogastrogram;④: gastric emptying rate.
Figure 2 Risk of bias of the included articles
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trol groups as the horizontal coordinate, and the recip-
rocal of OR as the vertical ordinate. Publication bias
was identified by the funnel plot. The results showed
that the reversed funnel-shape plot was generally sym-
metrical, indicating the included studies had almost no
publication bias (Figure 5).
Adverse reactions
Adverse reactions such as gastrointestinal symptoms
and headache were reported in the control groups of
two studies,6,12 but not in any other articles.
DISCUSSION
FD includes the presence of symptoms originating in
the gastroduodenal region with no evidence of structur-
al disease explaining the symptoms, according to the
RomeⅢ criteria.16 In the general population, the prev-
alence of dyspepsia is estimated to be 20%-40%, and
most patients are believed to have FD.17 FD reduces pa-
tient quality of life and imparts a significant economic
burden to families and the state.18 About one billion
pounds are spent in evaluating and treating dyspepsia
in UK every year, according to the data from the Leeds
UK help study.19 However, the pathogenesis of FD is
not fully understood, and prokinetic agents are still the
most common medication, despite their unsatisfactory
results. Nevertheless, TCM could provide a new meth-
od for treating FD.
According to TCM, poor living habits such as endoge-
nous injury by the seven emotions, improper diet, and
maladjustment of work may be important factors injur-
ing the spleen and the stomach. The spleen, which is
regarded as the acquired foundation, governs transpor-
tation, transformation, and blood, and ascends usable
substances. Stomach, the sea of water and grain, domi-
nates not only the reception and digestion of food, but
also the ascending and descending of Qi activities. The
stomach and spleen assist each other in absorption and
distribution. Pathogenic factors first result in Qi defi-
ciency in the spleen and stomach, followed by patho-
logical changes from Qi stagnation, resulting from the
impeded flow of deficient Qi, and cold syndrome, aris-
ing from deficient Qi. Banxiaxiexin Tang, from Shang
Han Lun, is an important formula for treating fullness
with accumulation of intermingled cold and heat due
to spleen and stomach asthenia.3 Among the ingredi-
ents of Banxiaxiexin Tang, Huangqin (Radix Scutellari-
ae Baicalensis) and Huanglian (Rhizome Coptidis) clear
heat; Banxia (Rhizome Pinelliae) and Ganjiang (Rhi-
zoma Zingiberis) dispel accumulation and cold; Rensh-
en (Radix Ginseng), Gancao (Radix Glycyrrhizae), and
Dazao (Fructus Jujubae) benefit Qi and cure asthenia.
This formula possesses both cold and warm drugs and
bitter and acrid drugs with descending and expelling ef-
fects to invigorate Qi.
This meta-analysis included ten RCTs with a total of
972 patients. All articles had relatively identical diagno-
sis standards and judged curative effects by explicit in-
clusion and exclusion criteria. Unified standards make
the results more credible. The current data showed that
Banxiaxiexin Tang had a better effect than Western
Medicine in treating FD. However, most of the studies
are of poor methodological quality. Only two trials de-
scribed specific randomization methods, while the rest
mentioned randomization but lacked a description.
None of the trials described the implementation of allo-
cation concealment or blinding.
In summary, the results of this Meta-analysis suggest
Figure 5 Funnel plot of the effective rate
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Figure 4 Meta-analysis for comparison of effective rate between Banxiaxiexin Tang andWestern Medicine
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that Banxiaxiexin Tang has therapeutic benefits for FD
patients in terms of curative and effective rates, with
fewer adverse reactions. However, because of poor qual-
ity of the studies, further larger-scale and multi-cen-
tered RCTs with better methodological quality are re-
quired to provide more credible evidence.
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